Experts in regenerative medicine bring exceptional leadership to ARM Foundation to help increase understanding and acceptance of cell and gene medicine.
Washington, D.C., August 14, 2018 – The ARM Foundation for Cell & Gene Medicine (ARM Foundation), an independent 501(c)(3) non-profit organization, today announced five appointments to its Board of Directors: Amy DuRoss of Vineti; Brett Kopelan of debra of America; David Nagler, formerly of Audentes; Frank Sasinowski, M.S., M.P.H., J.D. of Hyman, Phelps and McNamara and Claudia Zylberberg of Akron Biotech.
The appointees will work with ARM Foundation Board Members and its leadership team to deliver on the organization’s mission of providing education and research that will accelerate patient access to safe, efficacious and potentially curative cell and gene therapies, tissue- engineered products and organ regeneration.
“We are honored that these experienced leaders in the cell and gene medicine community will lend their expertise to the important work of the ARM Foundation,” said Stewart Parker, chair of the ARM Foundation Board of Directors. “Each of them brings a unique perspective, deep commitment and enthusiasm to engage, inform, and empower the public and other stakeholders on key scientific, clinical, and regulatory issues that affect the advancement and acceptance of cell and gene medicines as viable and transformative treatment options.”
The newly appointed Board members will also serve on steering committees that will guide the ARM Foundation’s initial projects including a gene medicine education program; an in- depth impact analysis of cell and gene therapies and other regenerative medicines on national and international healthcare economies; and research to identify and prioritize the infrastructure, logistics, and healthcare system requirements for wide-scale adoption of transformative medicines.
About the ARM Foundation for Cell and Gene Medicine (ARM Foundation)
The ARM Foundation for Cell and Gene Medicine is an independent, 501(c)(3) non-profit organization dedicated to providing education and research that will accelerate patient access to safe, efficacious and potentially curative therapies. Its programs engage, educate and empower patients, caregivers, industry leaders and other stakeholders to help advance the science and benefits of gene therapy, gene editing, cell therapy, tissue-engineering and organ regeneration. By increasing understanding and acceptance of these transformative technologies, the Foundation hopes to involve more people in the clinical trial process and therefore help expedite the development of life-saving therapies. To learn more, visit http://www.thearmfoundation.org.